Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Metastatic NSCLC therapy, tepotinib, given Breakthrough Designation

europeanpharmaceuticalreviewSeptember 12, 2019

Tag: cancer , therapy , NSCLC , Lung , tepotinib

PharmaSources Customer Service